LTBAs must display a boxed warning from the U.S. Food and Drug Administration due to the:
A) Risk of life-threatening dermatological reactions
B) Increased incidence of cardiac events when LTBAs are used
C) Increased risk of asthma-related deaths when LTBAs are used
D) Risk for life-threatening alterations in electrolytes
Correct Answer:
Verified
Q1: A patient taking theophylline for his persistent
Q2: When prescribing montelukast (Singulair) for asthma, patients
Q3: The known drug interactions with the inhaled
Q4: Second generation antihistamines such as loratadine (Claritin)
Q6: Tiotropium bromide (Spiriva) is an inhaled anticholinergic:
A)Used
Q7: A 42-year-old patient has moderate persistent asthma.
Q8: Digoxin levels need to be monitored closely
Q9: Patients with allergic rhinitis may benefit from
Q10: A 72-year-old male occasionally takes diphenhydramine for
Q11: When recommending dimenhydrinate (Dramamine) to treat motion
Unlock this Answer For Free Now!
View this answer and more for free by performing one of the following actions
Scan the QR code to install the App and get 2 free unlocks
Unlock quizzes for free by uploading documents